此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

(2R,6R)-HNK（突触谷氨酸释放增强剂）在难治性抑郁症中的抗抑郁作用研究

2026年10月2日 更新者：National Institute of Mental Health (NIMH)

(2R,6R)-HNK（一种突触谷氨酸释放增强剂）在难治性抑郁症中的抗抑郁作用研究

Background:

Major depressive disorder (MDD) is a serious mental illness that can put people at risk of self-harm and death. Many drugs are used to treat MDD, but it can take a long time for them to be effective. Researchers want to know if a faster-acting drug, (2R,6R)-hydroxynorketamine (HNK), can better treat the symptoms of MDD.

Objective:

To test a study drug (HNK) in people with MDD.

Eligibility:

People aged 18 to 70 years with MDD. They must have had a screening assessment under protocol 01-M-0254.

Design:

Participants will be tapered off their current MDD drugs over 2 to 5 weeks. They will stay off of the drugs for up to 2 weeks prior to starting the study medication and procedures. They will have a physical exam with blood tests. They will have tests of their heart function, mood, and thinking. They will answer questions about their symptoms. They may choose to have imaging scans and scans of their brain activity.

HNK is given through a tube attached to a needle inserted into a vein. Participants will receive infusions on this schedule:

They will receive 4 infusions over 2 weeks. They will stay in the clinical center overnight after each infusion or for the duration of the study.

They will receive no drugs for 2 to 3 weeks.

They will have 4 more infusions over 2 weeks, with overnight stays after each or for the duration of the study.

One set of 4 infusions will be the HNK. The other set of 4 infusions will be a placebo. A placebo looks just like the real drug but contains no medicine. Participants will not know when they are getting the HNK or placebo.

...

研究概览

地位

招聘中

条件

干预/治疗

详细说明

Study Description

This is a randomized, double-blind, placebo-controlled, crossover, single-site study.

This experimental study will assess the efficacy and safety of two weeks of 0.25 to 2.0 mg/kg (2R,6R)-hydroxynorketamine (HNK), an enhancer of synaptic glutamate release. The study may be conducted on an inpatient or outpatient basis.

Objectives

Primary Objective

The primary objective is to evaluate the ability of (2R,6R)-HNK, an enhancer of synaptic glutamate release, to improve overall depressive symptomatology in participants with major depressive disorder (MDD). The efficacy of a two-week course of (2R,6R)-HNK will be compared to two weeks of saline placebo in a crossover study. Montgomery-Asberg Depression Rating Scale (MADRS) score will serve as the main outcome measure.

Secondary Objectives

  1. To evaluate the antidepressant efficacy of (2R,6R)-HNK at days 0 (230 min), 1, 2, 3, 4, 7, 8, 10, 11, and 12 compared to placebo in a crossover study, as assessed by change from baseline on MADRS total scores.
  2. To determine whether (2R,6R)-HNK demonstrates superior antidepressant efficacy compared to placebo in a crossover study, as assessed by the proportion of participants in remission (defined as MADRS total score <=10).
  3. To determine whether antidepressant response to (2R,6R)-HNK is superior to response to placebo in a crossover study, as assessed by the proportion of participants achieving response (defined as a >=50% reduction from baseline in MADRS total score).
  4. To evaluate the antisuicidal ideation effects of (2R,6R)-HNK at days 0 (230 min), 1, 2, 3, 4, 7, 8, 10, 11, and 12 compared to placebo in a crossover study, as assessed by change from baseline on item 10 (suicidality) of the MADRS, the Columbia Suicide Severity Rating Scale (C-SSRS), and the Scale for Suicide Ideation (SSI).
  5. To investigate the effects of (2R,6R)-HNK on mood, anxiety, and anhedonia symptoms at days 0 (230 min), 1, 2, 3, 4, 7, 8, 10, 11, and 12 compared to placebo in a crossover study, as assessed by change from baseline on the Beck Depression Inventory Second Edition (BDI-II), Hamilton Depression Rating Scale (HDRS), Hamilton Anxiety Rating Scale (HAM-A), Positive and Negative Affect Schedule (PANAS), Snaith-Hamilton Pleasure Scale (SHAPS), and the Temporal Experience of Pleasure Scale (TEPS), as well as change from baseline on various cognitive tasks (Auditory, Somatosensory, and Visual Evoked Fields Task, Monetary Incentive Delay (MID) task, Hariri Hamer task, and Probabilistic Reward Task (PRT)).
  6. To assess the safety and tolerability of a two-week course of (2R,6R)-HNK compared to placebo in a crossover study by incidence of adverse events (AEs) and total scores on the Clinician Administered Dissociative States Scale (CADSS), Young Mania Rating Scale (YMRS), Brief Psychiatric Rating Scale (BPRS), vital signs, changes in clinical laboratory evaluations, and electrocardiograms (ECGs).
  7. To assess the analgesic efficacy of (2R,6R)-HNK compared to placebo on days -1, 1, 4, 8, and 11, as assessed by pain measures during quantitative sensory testing and brain-based biomarkers for pain measured with fMRI on day 4 and day 11.

Endpoints

Endpoints Primary Endpoint

Effect of drug on the MADRS total score at day 12.

Secondary Endpoints

  • Proportion of subjects in remission (defined as MADRS total score <=10) at days 0 (230 min), 1, 2, 3, 4, 7, 8, 10, 11, and 12.
  • Proportion of subjects with response (defined as >=50% reduction from baseline in MADRS total score) at days 0 (230 min), 1, 2, 3, 4, 7, 8, 10, 11, and 12.
  • Effect of drug on MADRS total scores at days 0 (230 min), 1, 2, 3, 4, 7, 8, 10, 11, and 12.
  • Effect of drug on HDRS, BDI-II, BPRS, CADSS, C-SSRS, HAM-A, PANAS, SHAPS, SSI, TEPS, and YMRS total scores, and the MADRS item 10 (suicidality) at days 0 (230 min), 1, 2, 3, 4, 7, 8, 10, 11 and 12.
  • Effect of drug on the Auditory, Somatosensory, and Visual Evoked Fields Task, MID task, Hariri Hamer task, and PRT.
  • Incidence and nature of adverse events; vital signs; weight and body mass index (BMI) changes; physical examination changes; clinical laboratory evaluations; ECG.
  • Effect of drug on acute pain measures derived from Quantitative Sensory Testing (QST) at days -1, 1, 4, 8, and 11.

Surrogate Markers of Drug Effect, Target Engagement, and Antidepressant Response

  • Change in magnetoencephalography (MEG) spectral power (gamma power).
  • Change in brain glutamate levels using magnetic resonance spectroscopy (MRS).
  • Change in resting and task-based functional connectivity in functional magnetic resonance imaging (fMRI).
  • Change in peripheral biomarkers.
  • Change in brain-based biomarkers for pain.

研究类型

介入性

注册 (估计的)

50

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习联系方式

学习地点

  • 美国
    • Maryland
      • Bethesda、Maryland、美国、20892
        • 招聘中
        • National Institutes of Health Clinical Center
        • 接触：
          • NIH Clinical Center Office of Patient Recruitment (OPR)
          • 电话号码：TTY dial 711 800-411-1222
          • 邮箱：ccopr@nih.gov

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 70年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

  • INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  1. Ability of participant to understand and willingness to sign a written informed consent document. To verify this, participants must score >= 80% on the consent quiz.
  2. Stated willingness to comply with all study procedures and availability for the duration of the study.
  3. 18 to 70 years of age.
  4. All participants must have undergone a screening assessment under protocol 01-M-0254.
  5. Participants must fulfill DSM-IV or DSM-5 criteria for MDD, single episode or recurrent without psychotic features, based on clinical assessment and confirmed by a structured diagnostic interview (SCID-P). Participants must be experiencing a current major depressive episode lasting at least two weeks.
  6. Participants must have an initial score of >= 20 on the MADRS and a YMRS score of <12 within one week of study entry and upon entry into Phase II.
  7. Ability to take intravenous medication and be willing to adhere to the (2R,6R)-HNK regimen.
  8. Participants must have a current or past history of lack of response to at least one adequate antidepressant trial (may be from the same chemical class), with at least one in the current major depressive episode, operationally defined using the modified Antidepressant Treatment History Form (ATHF); non-response to an adequate trial of ECT or TMS would count as an adequate antidepressant trial.
  9. For individuals of reproductive potential: use of highly effective contraception starting at the time of enrollment and agreement to use such a method during study participation and for an additional four weeks after the end of Study Phase II.
  10. For males of reproductive potential: use of condoms or other methods from the time of enrollment to ensure effective contraception with partner, and for an additional 90 days after the end of Phase II.
  11. Agreement to adhere to Lifestyle Considerations throughout study duration.
  12. Medically healthy, or with stable, treated, chronic medical conditions (provided any medications are not excluded)

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

  1. Current use of disallowed concomitant medications or transcranial magnetic stimulation (TMS) two weeks prior to the start of Phase II.

  2. Treatment with a reversible monoamine oxidase inhibitor (MAOI) four weeks prior to the start of Phase II.

  3. Treatment with fluoxetine, aripiprazole, or brexpiprazole five weeks prior to the start of Phase II.

  4. Treatment with clozapine or electroconvulsive therapy (ECT) four weeks prior to the start of Phase II.

  5. Ongoing treatment with moderate or strong CYP3A4/5 inhibitors or inducers

  6. Lifetime history of deep brain stimulation.

  7. Previous antidepressant non-response to ketamine or esketamine (full course).

  8. No structured psychotherapy will be permitted during the total duration of the study. Participants unable or unwilling to stop psychotherapy will be unable to participate in the study.

  9. Pregnancy or lactation.

  10. Current psychotic features or a diagnosis of schizophrenia or any other psychotic disorder as defined in the DSM-IV or DSM-5.

  11. Participants with a history of DSM-IV substance or alcohol abuse or dependence, or DSM-5 substance use disorder (except for caffeine, nicotine, or cannabis), or moderate to severe alcohol use disorder, within the preceding three months. In addition, participants who are currently using drugs (except for caffeine, nicotine, or cannabis) must not have used illicit substances or known drugs of abuse in the two weeks prior to screen and must have a negative drug urine test (except for prescribed benzodiazepines or stimulants) prior to starting Phase II. Cannabis use is exclusionary if the use is daily, or if participants are unable to abstain during the study, or if function of daily life is impaired by use as determined by a clinician. Due to the interactions between cannabis and SSRIs, frequent cannabis use during previous antidepressant treatment will result in that treatment being considered a failed trial for eligibility purposes.

  12. Participants with a DSM-IV or DSM-5 Axis II diagnosis of borderline or antisocial personality disorder.

  13. Participants with a history of head injury that resulted in loss of consciousness exceeding five minutes (for the imaging component of the study).

  14. No serious, unstable medical illnesses including but not limited to the following body systems and organs or those that in the judgment of the Principal Investigator pose a risk to the participant's ability to safely participate in the study: Hepatic diseases (e.g. active viral hepatitis infection or cirrhosis of the liver, any liver disease with Child-Pugh score >=5), cardiovascular disease (including ischemic heart disease, coronary artery disease, congestive heart failure, poorly controlled hypertension due to risk of further blood pressure elevation and increase in demand on cardiac function from study drug), renal/urologic (e.g chronic kidney disease or acute kidney injury, history of bladder dysfunction due to theoretical risk of ketamine-induced cystitis, moderate to severe renal impairment of any etiology), endocrinologic (including uncontrolled diabetes due to association with progressive abnormality of the microvasculature and nervous system), or neurologic disease (e.g. elevated intraocular pressure or history of or presence of diseases that are associated with elevated intracranial pressure).

  15. Participants with unstable clinical hyperthyroidism or hypothyroidism.

  16. Participants with one or more seizures without a clear and resolved etiology.

  17. Clinically significant abnormal laboratory tests specifically defined by:

    • Alkaline phosphatase (Alk Phos) > 150 U/L
    • Alanine aminotransferase (ALT) > 55 U/L
    • Aspartate aminotransferase (AST) > 34 U/L
    • Total bilirubin (TB) > 1.2 mg/dL
    • Direct bilirubin (DB) > 0.5 mg/dL
    • 25-hydroxyvitamin D < 20 ng/mL
    • Folate < 2ng/mL
    • Vitamin B12 < 200 pg/mL

  18. Moderate to severe renal impairment with body surface area corrected eGFR <60mL/min.

  19. Participants who, in the Principal Investigator's judgment, pose a current serious suicidal or homicidal risk.

  20. Positive HIV test.

  21. Contraindications to MRS (metal in body, claustrophobia, etc. for imaging)

  22. Participants with COVID-19 or suspected COVID-19

  23. Inability to read and understand English. Non- English speakers will not be eligible as most of the required monitoring and rating instruments are not validated in languages other than English.

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

  • 主要用途：治疗
  • 分配：随机化
  • 介入模型：交叉作业
  • 屏蔽：三倍

武器和干预

参与者组/臂
干预/治疗
实验性的：1

Individuals in Arm 1 will receive double-blinded (2R,6R)-HNK infusions four times over two weeks during Test Session 1 and daily double-blinded placebo infusions four times over two weeks during Test Session 2. The starting dose will be 0.25 mg/kg and the treatment target for all participants will be 2.0 mg/kg. If response criteria is not met by the morning of the next infusion, the dose may be increased. Doses will be decreased if tolerability issues arise.
药品：(2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg)

Arm 1 and 2 Experimental Intervention

药品：Placebo

Arm 1 and 2 Control Intervention
实验性的：2

Individuals in Arm 2 will receive double-blinded placebo infusions four times over two weeks during Test Session 2 and double-blinded (2R,6R)-HNK infusions four times over two weeks during Test Session 1. The starting dose will be 0.25 mg/kg and the treatment target for all participants will be 2.0 mg/kg. If response criteria is not met by the morning of the next infusion, the dose may be increased. Doses will be decreased if tolerability issues arise.
药品：(2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg)

Arm 1 and 2 Experimental Intervention

药品：Placebo

Arm 1 and 2 Control Intervention

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
Change from baseline on Montgomery-Asberg Depression Rating Scale total scores
大体时间：Baseline, Day 12

Clinical rating scale of depression
Baseline, Day 12

次要结果测量

结果测量
措施说明
大体时间
Incidence of AEs and total scores using the Clinician Administered Dissociative States Scale, Young Mania Rating Scale, Brief Psychiatric Rating Scale, vital signs, changes in clinical laboratory evaluations, and electrocardiograms.
大体时间：Baseline, 230 min post-drug, and Days 1, 2, 3, 4, 7, 8, 10, 11, and 12, per Test Session.

Measures and evaluations assess various aspects of clinical condition, adverse events, and mood and anxiety symptomology
Baseline, 230 min post-drug, and Days 1, 2, 3, 4, 7, 8, 10, 11, and 12, per Test Session.
Change from baseline on the Hamilton Depression Rating Scale, Hamilton Anxiety Rating Scale, Positive and Negative Affect Schedule, Snaith-Hamilton Pleasure Scale, Temporal Experience of Pleasure Scale, and cognitive tasks.
大体时间：Baseline, 230 min post-drug, and Days 1, 2, 3, 4, 7, 8, 10, 11, and 12, per Test Session.

Clinical rating scales of mood, anxiety, and anhedonia
Baseline, 230 min post-drug, and Days 1, 2, 3, 4, 7, 8, 10, 11, and 12, per Test Session.
Change from baseline on item 10 (suicidality) of the Montgomery-Asberg Depression Rating Scale and total score on the Columbia Suicide Severity Rating Scale and the Scale for Suicide Ideation.
大体时间：Baseline, 230 min post-drug, and Days 1, 2, 3, 4, 7, 8, 10, 11, and 12, per Test Session.

Clinical rating scales of depression and suicidality
Baseline, 230 min post-drug, and Days 1, 2, 3, 4, 7, 8, 10, 11, and 12, per Test Session.
Proportion of participants achieving response (defined as a >/=50% reduction from baseline in Montgomery-Asberg Depression Rating Scale total score)
大体时间：Baseline, 230 min post-drug, and Days 1, 2, 3, 4, 7, 8, 10, 11, and 12, per Test Session.

Clinical rating scale of depression
Baseline, 230 min post-drug, and Days 1, 2, 3, 4, 7, 8, 10, 11, and 12, per Test Session.
Proportion of participants in remission (defined as Montgomery-Asberg Depression Rating Scale total score =10)
大体时间：Baseline, 230 min post-drug, and Days 1, 2, 3, 4, 7, 8, 10, 11, and 12, per Test Session.

Clinical rating scale of depression
Baseline, 230 min post-drug, and Days 1, 2, 3, 4, 7, 8, 10, 11, and 12, per Test Session.
Change from baseline on Montgomery-Asberg Depression Rating Scale total scores
大体时间：Baseline, 230 min post-drug, and Days 1, 2, 3, 4, 7, 8, 10, 11, and 12, per Test Session.

Clinical rating scale of depression
Baseline, 230 min post-drug, and Days 1, 2, 3, 4, 7, 8, 10, 11, and 12, per Test Session.
Pain thresholds and tolerance during quantitative sensory testing.
大体时间：Baseline and Days 1, 4, 8, and 11, per Test Session.

Measures assess acute pain in response to noxious stimuli.
Baseline and Days 1, 4, 8, and 11, per Test Session.
Pain thresholds and tolerance during quantitative sensory testing while undergoing fMRI.
大体时间：Days 4 and 11, per Test Session

fMRI procedures to evaluate dose-dependent effects of HNK on analgesia.
Days 4 and 11, per Test Session

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

National Institute of Mental Health (NIMH)

调查人员

  • 首席研究员：Carlos A Zarate, M.D.、National Institute of Mental Health (NIMH)

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

有用的网址

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年11月6日

初级完成 (估计的)

2027年7月1日

研究完成 (估计的)

2027年7月1日

研究注册日期

首次提交

2024年7月19日

首先提交符合 QC 标准的

2024年7月19日

首次发布 (实际的)

2024年7月22日

研究记录更新

最后更新发布 (实际的)

2026年10月5日

上次提交的符合 QC 标准的更新

2026年10月2日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

关键字

其他相关的 MeSH 术语

其他研究编号

  • 10001602
  • 001602-M

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)？

是的

IPD 计划说明

Clinical and demographic and biomarker participant data collected during the trial, after deidentification.

IPD 共享时间框架

Starting within 1 year of completion of the study.

IPD 共享访问标准

Branch Chief will review requests and access will need to be approved by the NIMH/DIRP SD and OCD NIMH and the NIH IRB.

IPD 共享支持信息类型

  • 树液

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅